Listed

Eledon Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 8, 2017 and accepted by EDGAR at Nov 8, 2017, 16:41 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-07-01 to 2017-09-30$517.0kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-01-01 to 2017-09-30$1.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-07-01 to 2017-09-30−$3.0mus-gaap:OperatingIncomeLoss
Operating income9 months2017-01-01 to 2017-09-30−$11.0mus-gaap:OperatingIncomeLoss
Net income3 months2017-07-01 to 2017-09-30−$3.0mus-gaap:NetIncomeLoss
Net income9 months2017-01-01 to 2017-09-30−$11.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2017-07-01 to 2017-09-30−$0.43us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2017-01-01 to 2017-09-30−$2.25us-gaap:EarningsPerShareBasicAndDiluted
Cash and equivalentsAt period end2017-09-30$19.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-09-30$21.0mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$23.0mus-gaap:Assets
Current liabilitiesAt period end2017-09-30$2.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-09-30$2.4mus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30$20.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-17-022799. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.